CDIOW · Insider Trading
Cardio Diagnostics Holdings Inc. Warrant
Every open-market purchase and sale reported by CDIOW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | James Intrater | Director | A | +3,205 deriv. | — |
| 2026-04-02 | Wendy J Betts | Director | A | +3,205 deriv. | — |
| 2026-04-02 | Paul Frederick Burton | Director | A | +3,205 deriv. | — |
| 2026-04-02 | Peter K Fung | Director | A | +3,205 deriv. | — |
| 2026-01-06 | Wendy J Betts | Director | A | +2,306 deriv. | — |
| 2026-01-06 | James Intrater | Director | A | +2,306 deriv. | — |
| 2026-01-06 | Peter K Fung | Director | A | +2,306 deriv. | — |
| 2026-01-06 | Paul Frederick Burton | Director | A | +2,306 deriv. | — |
| 2025-10-03 | Paul Frederick Burton | Director | A | +1,559 deriv. | — |
| 2025-10-03 | James Intrater | Director | A | +1,559 deriv. | — |
| 2025-10-03 | Wendy J Betts | Director | A | +1,559 deriv. | — |
| 2025-10-03 | Peter K Fung | Director | A | +1,559 deriv. | — |
| 2025-07-02 | Wendy J Betts | Director | A | +1,736 deriv. | — |
| 2025-07-02 | Peter K Fung | Director | A | +1,736 deriv. | — |
| 2025-07-02 | Paul Frederick Burton | Director | A | +1,736 deriv. | — |
| 2025-07-02 | James Intrater | Director | A | +1,736 deriv. | — |
| 2025-04-01 | James Intrater | Director | A | +18,939 deriv. | — |
| 2025-04-01 | Wendy J Betts | Director | A | +18,939 deriv. | — |
| 2025-04-01 | Peter K Fung | Director | A | +18,939 deriv. | — |
| 2025-04-01 | Paul Frederick Burton | Director | A | +18,939 deriv. | — |
| 2025-01-15 | James Intrater | Director | A | +4,544 deriv. | — |
| 2025-01-15 | Paul Frederick Burton | Director | A | +4,544 deriv. | — |
| 2024-10-10 | James Intrater | Director | A | +18,686 deriv. | — |
| 2024-10-10 | Paul Frederick Burton | Director | A | +18,686 deriv. | — |
| 2024-10-10 | Stanley K. Lau | Director | A | +18,686 deriv. | — |
| 2024-10-10 | Oded Levy | Director | A | +18,686 deriv. | — |
| 2024-10-09 | Timur Dogan | Chief Technology Officer | Buy | +68,965 | +$20.00K |
| 2024-10-08 | Meeshanthini Dogan | Chief Executive Officer | Buy | +68,965 | +$20.00K |
| 2024-10-07 | Meeshanthini Dogan | Chief Executive Officer | Buy | +68,965 | +$20.00K |
| 2024-09-23 | Timur Dogan | Chief Technology Officer | Buy | +68,965 | +$20.00K |
| 2024-09-10 | Robert Philibert | Chief Medical Officer | Buy | +34,075 | +$9.76K |
| 2024-09-09 | Meeshanthini Dogan | Chief Executive Officer | Buy | +68,965 | +$20.00K |
| 2024-09-09 | Meeshanthini Dogan | Chief Technology Officer | Buy | +68,965 | +$20.00K |
| 2024-07-02 | James Intrater | Director | A | +7,575 deriv. | — |
| 2024-07-02 | Oded Levy | Director | A | +7,575 deriv. | — |
| 2024-07-02 | Paul Frederick Burton | Director | A | +7,575 deriv. | — |
| 2024-07-02 | Stanley K. Lau | Director | A | +7,575 deriv. | — |
| 2024-04-08 | James Intrater | Director | M | +8,803 | +$12.50K |
| 2024-04-08 | Paul Frederick Burton | Director | M | +8,803 | +$12.50K |
| 2024-04-08 | Stanley K. Lau | Director | M | +8,803 | +$12.50K |
| 2024-04-08 | Oded Levy | Director | M | +8,803 | +$12.50K |
| 2024-02-21 | Elisa V Luqman | Chief Financial Officer | A | +35,719 deriv. | — |
| 2024-02-21 | Paul Frederick Burton | Director | A | — | — |
| 2024-02-21 | Warren Hosseinion | Director | A | +35,719 deriv. | — |
| 2024-02-21 | Oded Levy | Director | A | — | — |
| 2024-02-21 | Khullani Abdullahi | VP of Revenue and Strategy | A | +238,128 deriv. | — |
| 2024-02-21 | Robert Philibert | Chief Medical Officer | A | +142,876 deriv. | — |
| 2024-02-21 | Meeshanthini Dogan | Chief Executive Officer | A | +714,384 deriv. | — |
| 2024-02-21 | Stanley K. Lau | Director | A | — | — |
| 2024-02-21 | James Intrater | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| James Intrater | Director | 71,596 | $694 |
| Paul Frederick Burton | Director | 8,803 | $85 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CDIOW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.